サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：非小細胞肺癌 (NSCLC) の世界市場：2022-2028年
市場調査レポート
商品コード
1123120

非小細胞肺癌 (NSCLC) の世界市場：2022-2028年

Global Non-Small Cell Lung cancer Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 140 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
非小細胞肺癌 (NSCLC) の世界市場：2022-2028年
出版日: 2022年07月22日
発行: Orion Market Research
ページ情報: 英文 140 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非小細胞肺癌 (NSCLC) の市場規模は予測期間中に9.6％のCAGRで成長すると予測されています。

NSCLC治療薬の進化、大気汚染の増加、タバコ、パイプ、葉巻の喫煙、職場におけるアスベスト、ヒ素、クロム、ベリリウム、ニッケル、すす、タール、放射線への暴露などの要因が同市場の成長を推進しています。また、遺伝性の原因やHIV感染も同市場を牽引しています。

当レポートでは、世界の非小細胞肺癌 (NSCLC) の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

  • 主要企業分析
  • 主要戦略分析
  • COVID-19の主要企業への影響

第4章 市場決定要因

  • 推進要因
  • 抑制要因
  • 機会

第5章 市場分析：区分別

  • 世界の非小細胞肺癌 (NSCLC) 市場：タイプ別
    • 腺癌
    • 扁平上皮癌
    • 大細胞癌
    • その他
  • 世界の非小細胞肺癌 (NSCLC) 市場：治療別
    • 化学療法
    • 標的療法
    • 放射線療法
    • 手術
    • 凍結手術
    • その他
  • 世界の非小細胞肺癌 (NSCLC) 市場：診断別
    • CTスキャン
    • X線
    • 喀痰細胞診
    • 気管支鏡検査
    • 臨床検査
    • 胸腔鏡検査
    • その他
  • 世界の非小細胞肺癌 (NSCLC) 市場：エンドユーザー別
    • 総合病院
    • 癌研究センター

第6章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • AbbVie Inc.
  • Agena Bioscience, Inc.
  • Arqule Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biodesix, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • DAIICHI SANKYO CO. LTD.
  • Eli Lilly and Co.
  • Exosome Diagnostics Corp.
  • F. Hoffman-La Roche, Inc.
  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Illumina, Inc.
  • Merck & Co., Inc.
  • Novartis International Ag
  • Personal Genome Diagnostics Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Sanofi SA
  • SAGA Diagnostics AB
  • Thermo Fisher Scientific Inc.
図表

LIST OF TABLES

  • 1. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL ADENOCARCINOMAS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL SQUAMOUS CELL CARCINOMA NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL LARGE CELL CARCINOMAS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL OTHERS NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 8. GLOBAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL SURGERY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL CRYOSURGERY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL OTHERS THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 14. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 15. GLOBAL CT SCAN INNON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 16. GLOBAL X-RAYS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 17. GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 18. GLOBAL BRONCHOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 19. GLOBAL LABORATORY TESTS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 20. GLOBAL THORACOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 21. GLOBAL OTHERS DIAGNOSIS IN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 22. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 23. GLOBAL NON-SMALL CELL LUNG CANCER IN MULTISPECIALTY HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 24. GLOBAL NON-SMALL CELL LUNG CANCER IN CANCER RESEARCH CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 25. GLOBAL NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICA NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 28. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 29. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 30. NORTH AMERICAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 31. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 32. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 33. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 34. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 35. EUROPEAN NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 38. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 39. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 40. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY THERAPY, 2020-2027 ($ MILLION)
  • 43. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 44. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL NON-SMALL CELL LUNG CANCER MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL NON-SMALL CELL LUNG CANCER MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL NON-SMALL CELL LUNG CANCER MARKET, 2020-2027 (%)
  • 4. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY THERAPY, 2020 VS 2027 (%)
  • 6. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 7. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY END-USER, 2020 VS 2027 (%)
  • 8. GLOBAL NON-SMALL CELL LUNG CANCER MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL ADENOCARCINOMAS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 10. GLOBAL SQUAMOUS CELL CARCINOMA NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 11. GLOBAL LARGE CELL CARCINOMAS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 12. GLOBAL OTHERS NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 13. GLOBAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 14. GLOBAL TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 15. GLOBAL RADIATION THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 16. GLOBAL SURGERY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 17. GLOBAL CRYOSURGERY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 18. GLOBAL OTHERS THERAPY FOR NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 19. GLOBAL CT SCAN IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 20. GLOBAL X-RAYS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 21. GLOBAL SPUTUM CYTOLOGY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 22. GLOBAL BRONCHOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 23. GLOBAL LABORATORY TESTS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 24. GLOBAL THORACOSCOPY IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 25. GLOBAL OTHERS DIAGNOSIS IN NON-SMALL CELL LUNG CANCER MARKET SHARE, 2020 VS 2027 (%)
  • 26. GLOBAL NON-SMALL CELL LUNG CANCER IN MULTISPECIALTY HOSPITALS MARKET SHARE, 2020 VS 2027 (%)
  • 27. GLOBAL NON-SMALL CELL LUNG CANCER IN CANCER RESEARCH CENTERS MARKET SHARE, 2020 VS 2027 (%)
  • 28. US NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. CANADA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. UK NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. FRANCE NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. GERMANY NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. ITALY NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 34. SPAIN NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. ROE NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 36. INDIA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 37. CHINA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 38. JAPAN NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 39. SOUTH KOREA NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 40. REST OF ASIA-PACIFIC NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD NON-SMALL CELL LUNG CANCER MARKET SIZE, 2020-2027 ($ MILLION)
目次
Product Code: OMR2017206

Global Non-Small Cell Lung Cancer Market Size, Share & Trends Analysis Report By Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), By Therapy (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Cryosurgery, and Others). By Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), By End-User (Multispecialty Hospitals and Cancer Research Centers) Forecast, 2021-2027

The global non-small cell lung cancer market is growing at a CAGR of 9.6% during the forecast period (2021-2027). NSCLC is a type of cancer that is most common among smokers as well as non-smokers group of people. NSCLC in comparison to the other form of cancer called small cell lung cancer grows and spreads less aggressively. Therefore, NSCLC has a better chance of treatment with surgery, chemotherapy, and other medical treatments. The major factor propelling the growth of the NSCLC market includes evolving drug landscape for the treatment of NSCLC. The major factors that are augmenting the growth of the market are the rise in air pollution, smoking cigarettes, pipes, or cigars, being in exposure to asbestos, arsenic, chromium, beryllium, nickel, soot, or tar in the workplace, and being exposed to radiation. Around 84% of the tumor is non-small cell lung cancer and most of the advanced stage is treated with chemotherapy, targeted drugs, and/or immunotherapy.

In addition to this, hereditary causes and being infected with HIV are another factor that drives the global non-small cell lung cancer diagnostics and therapeutics market. However, the high cost of drugs and treatment and the risk associated with it are some of the restraints that can challenge the growth of the market in the forecast period. Conversely rise in better chances of treatment with surgery, chemotherapy, and other medical treatments are estimated to be the opportunity for the market players. Moreover, the significant increase in the R&D activities supported by government organizations such as the American Lung Association, which has made support for lung cancer research its top priority, is also aiding with the growth of the market.

Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market

The global non-small lung cancer market is hardly hit by the COVID-19 pandemic since December 2019. Key industry therapy of non-small cell lung cancer includes chemotherapy, radiation therapy, surgery, and targeted therapy in top economies such as China, the US, and European Union. The COVID-19 pandemic in these major economies has led to delay in treatment across the globe. Moreover, the frequent visits to hospitals might considerably increase the risk of being infected due to which many patients themselves decided to delay the treatment. During the global pandemic, the 30-day mortality rate in patients with newly diagnosed NSCLC significantly increased with the pandemic from 25% before COVID-19 to 49% during COVID-19. However, the market will witness "W" shape recovery in near future owing to the increase in the number of patients who experienced a delay in treatment in major economies. The market will show a decline in share twice due to the most economies faced by the second wave. One of the growth opportunities includes the clinical guideline published by the National Institute for Health and Care Excellence (NICE) for the guidance of standard anticancer treatments to cancer patients with COVID-19 and to maximize the use of the available resources to sustain health services.

Segmental Outlook

The market is segmented based on type, therapy, diagnosis, and end-user. Based on the type segment, the market is segmented into adenocarcinomas, squamous cell carcinoma, large cell carcinomas, and others. Based on the therapy segment, the market is segmented into chemotherapy, targeted therapy, radiation therapy, surgery, cryosurgery, and others. Among these, the chemotherapy segment is anticipated to have significantly large shares during the forecast period. Based on the diagnosis segment, the market is segmented into CT scan, x-rays, sputum cytology, bronchoscopy, laboratory tests, thoracoscopy, and others. Further based on the end-user segment, the market is bifurcated into multispecialty hospitals and cancer research centers.

Global Non-Small Cell Lung Cancer Market Share by Type, 2020 (%)

Global Non-Small Cell Lung Cancer Market Share by Type

Adenocarcinomas segment to hold Lucrative Share in the Global NSCLC Market

The Adenocarcinomas segment hold a significant market share in 2020. According to the analysis of the LUNGevity Foundation, lung adenocarcinoma accounts for 40% of all lung cancers and is found mostly in women. Moreover, people aging between 20-46 who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers. Even taking the population of people who had never smoked, most of the lung cancer was adenocarcinomas. Some of the major companies that operate in this segment include Merck & Co., Inc., DAIICHI SANKYO CO. LTD., AstraZeneca, and Bristol Myers Squibb. For instance, in April 2021, FDA approved nivolumab manufactured by Bristol-Myers Squibb for esophageal adenocarcinoma. Moreover, in January 2021, Daiichi Sankyo received approval from FDA for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Regional Outlooks

The global NSCLC market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. Based on the geography, the market is bifurcated into North America (the US and Canada), Europe (Germany, Spain, Italy, France, the UK, and the Rest of Europe), Asia-Pacific (India, China, Japan South Korea, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East and Africa, and Latin America). North America is estimated to have the major share in the non-small cell lung cancer market. High investment by the market players, the large pool of patients, improved healthcare infrastructure, and increased government funding is some of the major factors that contribute to the share of the market. According to the American Society of Clinical Oncology's (ASCO) report published in 2020, NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnosed.

Global Non-Small Cell Lung Cancer Market Growth, by Region 2020-2026

Global Non-Small Cell Lung Cancer Market Growth, by Region

Asia-Pacific is projected to highest Contributor to the growth of the Global NSCLC market

Asia-Pacific is estimated to be one of the fastest-growing regions owing to the increase in the prevalence of lung cancer with an increase in population and less stringent government regulations. For instance, in 2020, a Phase 4, open-label, single-arm, multi-center, prospective clinical trial of dacomitinib started in India which is estimated to complete by the end of 2022. Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic NSCLC.

Market Players Outlook

Key players of the non-small cell lung cancer market include Eli Lilly and Co., Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca PLC, Novartis AG, and Bristol Myers Squibb Co., among others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to thrive in a competitive environment. For instance, in January 2020, Merck completed the acquisition of ArQule at a purchase price of $20.00 per share. Moreover, in November 2019, Bristol-Myers Squibb Completed the acquisition of one of the leading biopharma company Celgene.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global non-small cell lung cancer market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market Industry
  • Recovery Scenario of Global Non-Small Cell Lung Cancer Market Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Non-Small Cell Lung Cancer Market By Type
    • 5.1.1. Adenocarcinomas
    • 5.1.2. Squamous Cell Carcinoma
    • 5.1.3. Large Cell Carcinomas
    • 5.1.4. Others
  • 5.2. Global Non-Small Cell Lung Cancer Market By Therapy
    • 5.2.1. Chemotherapy
    • 5.2.2. Targeted Therapy
    • 5.2.3. Radiation Therapy
    • 5.2.4. Surgery
    • 5.2.5. Cryosurgery
    • 5.2.6. Others
  • 5.3. Global Non-Small Cell Lung Cancer Market By Diagnosis
    • 5.3.1. CT Scan
    • 5.3.2. X-Rays
    • 5.3.3. Sputum Cytology
    • 5.3.4. Bronchoscopy
    • 5.3.5. Laboratory Tests
    • 5.3.6. Thoracoscopy
    • 5.3.7. Others
  • 5.4. Global Non-Small Cell Lung Cancer Diagnosis And Therapeutics Market By End-User
    • 5.4.1. Multispeciality Hospitals
    • 5.4.2. Cancer Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Agena Bioscience, Inc.
  • 7.3. Arqule Inc.
  • 7.4. Amgen Inc.
  • 7.5. AstraZeneca PLC
  • 7.6. Bayer AG
  • 7.7. Biodesix, Inc.
  • 7.8. Boehringer Ingelheim International GmbH
  • 7.9. Bristol Myers Squibb Co.
  • 7.10. DAIICHI SANKYO CO. LTD.
  • 7.11. Eli Lilly and Co.
  • 7.12. Exosome Diagnostics Corp.
  • 7.13. F. Hoffman-La Roche, Inc.
  • 7.14. Genentech, Inc.
  • 7.15. GlaxoSmithKline PLC
  • 7.16. Illumina, Inc.
  • 7.17. Merck & Co., Inc.
  • 7.18. Novartis International Ag
  • 7.19. Personal Genome Diagnostics Inc.
  • 7.20. Pfizer Inc.
  • 7.21. Qiagen NV
  • 7.22. Sanofi SA
  • 7.23. SAGA Diagnostics AB
  • 7.24. Thermo Fisher Scientific Inc.